Recs

2
Player Avatar zzlangerhans (99.70) Submitted: 5/10/2011 1:30:03 PM : Underperform Start Price: $11.41 CYCC Score: +15.46

Cyclacel is carving out a new spike this month, undoubtedly related to ASCO's approach. But the company's presentations are unlikely to contain meaningful new data - the SEAMLESS phase III trial of sapacitabine in elderly AML was only initiated a few months ago. After ASCO, investors will have to confront a company with a pipeline comprised of two weak candidates. Seliciclib may vanish from the scene after topline results of the APPRAISE phase IIb trial showed no effect of progression-free survival and only a non-significant positive trend in overall survival. Meanwhile, the phase II data for sapacitabine in elderly AML was unimpressive - 30% one-year survival, which compares unfavorably to the 40% one-year survival reported for Vidaza in an earlier study. Only interim safety data for SEAMLESS is expected in 2011. Another dilutive financing is almost certain before SEAMLESS proceeds to completion.

Featured Broker Partners


Advertisement